➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson
Express Scripts
McKesson

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Patent: 5,252,475

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,252,475
Title: Methods and vectors for selectively cloning exons
Abstract:The invention relates to a method for selectively cloning exons in which an ukaryotic genomic DNA fragment to be assayed is cloned into a shuttle vector in a cloning site of an intron flanked by exons. Upon expression in eukaryotic cells, exons present in the cloned DNA are spliced to the exons flanking the intron. After amplification of the cDNA of the expressed mRNA with primers specific for the exons in the vector by PCR, selectively cloned exons can be detected due to the size of the PCR product. The invention also relates to vectors used to carry out the method of the invention as well as to exon libraries.
Inventor(s): Reth; Michael (Freiburg, DE)
Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V. (Gottingen, DE)
Application Number:07/725,608
Patent Claims:see list of patent claims

Details for Patent 5,252,475

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V. (Gottingen, DE) 2010-10-12 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V. (Gottingen, DE) 2010-10-12 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V. (Gottingen, DE) 2010-10-12 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Harvard Business School
Dow
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.